TENXNasdaqPharmaceutical PreparationsFiscal year ends December 31

TENAX THERAPEUTICS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026

$1.52+0.16 (+11.76%)

Close on Oct 19, 2026

Market cap: $77.32M
P/E (TTM): –
Dividend yield: –

TENAX THERAPEUTICS, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2015 2015-04-30	FY 2014 2014-04-30	FY 2013 2013-04-30	FY 2012 2012-04-30	FY 2011 2011-04-30
Revenue	0	0	–	–	–	–	–	–	–	0.05	0.16	1.19	0.36	0.10
Cost of Revenue	–	–	–	–	–	–	–	–	–	0	0.13	0.04	0.05	0.22
Gross Profit	–	–	–	–	–	–	–	–	–	0	-0.10	0.05	0.05	0.10
Research & Development	33	13	3.23	5.38	25	4.56	3.47	1.24	3.53	6.66	3.00	2.46	2.46	2.68
Selling, General & Admin	–	–	–	–	7.58	5.31	5.08	5.65	5.68	7.17	14	3.68	6.09	7.68
General & Administrative	24	6.79	5.01	5.68	7.58	–	–	–	–	–	–	–	–	–
Operating Expenses	56	19	8.23	11	33	9.87	8.56	6.89	9.21	15	17	6.38	8.58	11
Operating Income	-56	-19	-8.23	11	-33	9.87	-8.56	-6.89	-9.21	-15	-17	-5.19	-8.22	11
Interest Expense	0	0.02	0.02	0.00	0.00	0.00	0	–	–	0.05	2.21	4.24	7.41	-0.17
Other Non-Operating Income	-0.03	0.00	0.06	-0.01	–	0.02	0.16	0.08	0.37	0.78	-0.72	0.01	-0.08	-0.29
Merger & Restructuring Charges	–	–	–	–	–	–	–	–	–	–	–	0.22	–	–
Asset Impairment Charges	–	–	–	–	–	–	–	–	0	0.11	0	0.03	0.03	0.30
Gain (Loss) on Investments	–	–	–	–	–	0.00	0.00	-0.01	0.00	0.00	0	0	–	–
Gain (Loss) on Sale of Assets	–	0	0.00	0.00	–	0	0.00	0	0.00	0.01	0.00	-0.04	–	–
Income Tax Expense	0	0	0	0	0	0	0	0	0	0	0	–	–	–
Net Income incl. Noncontrolling Interests	-53	-18	-7.71	-11	-32	9.85	–	–	–	–	–	–	–	–
Net Income	-53	-18	-7.71	11	-32	-9.85	-8.39	-14	-8.84	-14	-20	-9.42	-16	10
Preferred Dividends	–	–	–	–	–	–	0	7.33	0	0	5.80	0.96	0.02	–
Net Income to Common	–	–	–	–	–	–	–	–	–	14	25	10	16	–
EPS (Basic)(per share)	-1.34	-1.15	-31.04	–	-1.58	-0.95	-1.35	-9.04	-6.27	-10.00	-54.20	-125.80	-242.40	-180.00
EPS (Diluted)(per share)	-1.34	-1.15	-31.04	–	-1.58	-0.95	-1.35	-9.04	-6.27	-10.00	-54.20	-133.60	-281.40	-180.00
Shares Outstanding (Basic, Weighted)(shares)	39	15	0.25	–	21	10	6.20	1.56	1.41	1.40	0.47	0.08	0.06	0.06
Shares Outstanding (Diluted, Weighted)(shares)	39	15	0.25	–	21	10	6.20	1.56	1.41	1.40	0.47	0.09	0.07	0.06
EBITDA	–	-19	-8.23	11	-33	9.87	-8.55	-6.88	-9.19	-15	-16	-5.04	-8.01	11
Net Interest Income	–	–	–	–	0.00	0.00	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -55.6%

Financial strength

Current ratio: 15.07
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 1461.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.68
Dividend yield: –